Skip to content
Menu

Ardelyx, Inc. ARDX

Full chart Compare
Set alert

Price alert · ARDX

All alert types
3.12 USD -0.06 (-1.89%)

Regular-session close

3.16 +0.04 +1.13%

Pre-market · Nov 19, 7:57 AM ET

3.09 Day range 3.26
2.80 52-week range 8.40
YTD
-46.48%
1 year
-46.30%

Discussion (240)

Obama ARDX 6 years ago #221

Don’t believe my words. Buy out is coming!!!

Obama ARDX 6 years ago #222

Cum on, just hit $13 so we can all move on

Obama ARDX 6 years ago #224

How do you know that’s a planned sale?

Obama ARDX 6 years ago #225

7% jump premarital jump. Some @holes have nothing better to do.

Obama ARDX 6 years ago #226

Price has been lingering around. Not sure if a buyout is possible.

Obama ARDX 6 years ago #227

Come on, I don’t care what your drug does. Just go up. Up up up.

Eric Danielson ARDX 7 years ago #228

Ardelyx to Host Analyst Day in New York
Management to Review Late Stage Clinical Development and Commercial Potential in Hyperphosphatemia, Pipeline Program in Hyperkalemia and Recent Approval in IBS-C

Ardelyx logo (PRNewsFoto/Ardelyx)
NEWS PROVIDED BY
Ardelyx
Oct 10, 2019, 16:00 ET
FREMONT, Calif., Oct. 10, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an Analyst Day on Thursday, Oct. 17, 2019, from 7:30 a.m. to 11:00 a.m. ET in New York City. This year's event will focus on a review of late stage clinical development and commercial potential in hyperphosphatemia, pipeline program in hyperkalemia and the recent approval of the Company's New Drug Application for tenapanor for the treatment of IBS-C. Leading nephrologist, Myles Wolf, M.D., Chief of Nephrology, Duke University, will offer a clinician's perspective on the challenges of treating hyperphosphatemia in patients with CKD on dialysis.

blake ARDX 7 years ago #229

Tomorrow will be down 30%

blake ARDX 7 years ago #230

Clays here. Not good

Sign in to join the discussion